| [1] |
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834. |
| [2] |
PRASAD D, NGUYEN MH. Epidemiology, pathogenesis, diagnosis, surveillance, and management of hepatocellular carcinoma associated with vascular liver disease[J]. Kaohsiung J Med Sci, 2021, 37( 5): 355- 360. DOI: 10.1002/kjm2.12368. |
| [3] |
TÜMEN D, HEUMANN P, GÜLOW K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma[J]. Biomedicines, 2022, 10( 12): 3202. DOI: 10.3390/biomedicines10123202. |
| [4] |
TURAJLIC S, SWANTON C. Metastasis as an evolutionary process[J]. Science, 2016, 352( 6282): 169- 175. DOI: 10.1126/science.aaf2784. |
| [5] |
LUGLI A, ZLOBEC I, BERGER MD, et al. Tumour budding in solid cancers[J]. Nat Rev Clin Oncol, 2021, 18( 2): 101- 115. DOI: 10.1038/s41571-020-0422-y. |
| [6] |
HASE K, SHATNEY C, JOHNSON D, et al. Prognostic value of tumor“budding” in patients with colorectal cancer[J]. Dis Colon Rectum, 1993, 36( 7): 627- 635. DOI: 10.1007/BF02238588. |
| [7] |
REGMI SM, REGMI P, PAUDYAL A, et al. Tumor budding is associated with poor prognosis and clinicopathologic factors in esophageal carcinoma: A meta-analysis[J]. Eur J Surg Oncol, 2024, 50( 12): 108668. DOI: 10.1016/j.ejso.2024.108668. |
| [8] |
OKCU O, ÖZTÜRK Ç, ŞEN B, et al. Tumor Budding is a reliable predictor for death and metastasis in invasive ductal breast cancer and correlates with other prognostic clinicopathological parameters[J]. Ann Diagn Pathol, 2021, 54: 151792. DOI: 10.1016/j.anndiagpath.2021.151792. |
| [9] |
GÜRÇAY N, ACAR LN, ÜNAL TDK, et al. High grade tumor budding is associated with poor survival in pathologic stage I lung adenocarcinoma[J]. Ann Diagn Pathol, 2023, 66: 152188. DOI: 10.1016/j.anndiagpath.2023.152188. |
| [10] |
KARAMITOPOULOU E, GLOOR B. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment[J]. Eur J Cancer, 2013, 49( 10): 2458- 2459. DOI: 10.1016/j.ejca.2013.03.028. |
| [11] |
KEMI N, ESKURI M, IKÄLÄINEN J, et al. Tumor budding and prognosis in gastric adenocarcinoma[J]. Am J Surg Pathol, 2019, 43( 2): 229- 234. DOI: 10.1097/PAS.0000000000001181. |
| [12] |
KAIRALUOMA V, KEMI N, POHJANEN VM, et al. Tumour budding and tumour-stroma ratio in hepatocellular carcinoma[J]. Br J Cancer, 2020, 123( 1): 38- 45. DOI: 10.1038/s41416-020-0847-1. |
| [13] |
JIANG D, XU SS, ZHANG CP, et al. Association between the expression levels of ADAMTS16 and BMP2 and tumor budding in hepatocellular carcinoma[J]. Oncol Lett, 2023, 25( 6): 256. DOI: 10.3892/ol.2023.13842. |
| [14] |
BERG KB, SCHAEFFER DF. Tumor budding as a standardized parameter in gastrointestinal carcinomas: More than just the colon[J]. Mod Pathol, 2018, 31( 6): 862- 872. DOI: 10.1038/s41379-018-0028-4. |
| [15] |
ALMANGUSH A, SALO T, HAGSTRÖM J, et al. Tumour budding in head and neck squamous cell carcinoma- a systematic review[J]. Histopathology, 2014, 65( 5): 587- 594. DOI: 10.1111/his.12471. |
| [16] |
ZLOBEC I, LUGLI A. Tumour budding in colorectal cancer: Molecular rationale for clinical translation[J]. Nat Rev Cancer, 2018, 18( 4): 203- 204. DOI: 10.1038/nrc.2018.1. |
| [17] |
NIRANJAN KC, RAJ M, HALLIKERI K. Prognostic evaluation of tumour budding in oral squamous cell carcinoma: Evidenced by CD44 expression as a cancer stem cell marker[J]. Pathol Res Pract, 2023, 251: 154883. DOI: 10.1016/j.prp.2023.154883. |
| [18] |
ALMAYOUF F. Tumor budding in upper gastrointestinal carcinomas: A systematic review and meta-analysis[J]. Cureus, 2024, 16( 9): e70422. DOI: 10.7759/cureus.70422. |
| [19] |
KOVEITYPOUR Z, PANAHI F, VAKILIAN M, et al. Signaling pathways involved in colorectal cancer progression[J]. Cell Biosci, 2019, 9: 97. DOI: 10.1186/s13578-019-0361-4. |
| [20] |
SUN JY, YIN C, LI J. Research progress on pathways related to proliferation and metastasis of hepatocellular carcinoma[J]. Clin J Med Offic, 2024, 52( 9): 982- 985. DOI: 10.16680/j.1671-3826.2024.09.29. |
| [21] |
HADDAD TS, van den DOBBELSTEEN L, ÖZTÜRK SK, et al. Pseudobudding: Ruptured glands do not represent true tumor buds[J]. J Pathol, 2023, 261( 1): 19- 27. DOI: 10.1002/path.6146. |
| [22] |
SHAKHPAZYAN N, MIKHALEVA L, BEDZHANYAN A, et al. Cellular and molecular mechanisms of the tumor stroma in colorectal cancer: Insights into disease progression and therapeutic targets[J]. Biomedicines, 2023, 11( 9): 2361. DOI: 10.3390/biomedicines11092361. |
| [23] |
ROGERS AC, WINTER DC, HEENEY A, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer[J]. Br J Cancer, 2016, 115( 7): 831- 840. DOI: 10.1038/bjc.2016.274. |
| [24] |
BOSCH SL, TEERENSTRA S, de WILT JH, et al. Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions[J]. Endoscopy, 2013, 45( 10): 827- 834. DOI: 10.1055/s-0033-1344238. |
| [25] |
KAUNDIYAL S, CHANDRA S, ARORA A. Study of tumor budding and its association with clinicopathological parameters in breast carcinoma[J]. Rev Assoc Med Bras(1992), 2024, 70( 7): e20240173. DOI: 10.1590/1806-9282.20240173. |
| [26] |
VASUDEVAN S, KANNAN K, RAGHAVAN AV, et al. Analyzing tumor budding scores in invasive breast carcinoma: A tertiary care center study in south India[J]. J Pharm Bioallied Sci, 2024, 16( Suppl 2): S1850- S1853. DOI: 10.4103/jpbs.jpbs_910_23. |
| [27] |
YAAGOUBI S EL, ZARYOUHI M, BENMAAMAR S, et al. Prognostic impact of tumor budding on Moroccan gastric cancer patients[J]. Clin Pathol, 2023, 16: 2632010 X 231184329. DOI: 10.1177/2632010X231184329. |
| [28] |
RATHOD GB, DESAI KN, SHRIVASTAVA A, et al. Correlation of tumor budding with known clinicopathological, histomorphological and hormonal receptor status in patients with invasive breast carcinoma[J]. Cureus, 2022, 14( 9): e29637. DOI: 10.7759/cureus.29637. |
| [29] |
KUMARGURU BN, RAMASWAMY AS, SHAIK S, et al. Tumor budding in invasive breast cancer- An indispensable budding touchstone[J]. Indian J Pathol Microbiol, 2020, 63( Supplement): S117- S122. DOI: 10.4103/IJPM.IJPM_731_18. |
| [30] |
de ASSIS EM, RODRIGUES M, VIEIRA JC, et al. Lymphatic vascular density, the expression of podoplanin and tumor budding in oral squamous cell carcinoma[J]. Head Neck Pathol, 2023, 17( 2): 371- 382. DOI: 10.1007/s12105-022-01511-z. |
| [31] |
ASSIS EM, RODRIGUES M, VIEIRA JC, et al. Microvascular density and tumor budding in oral squamous cell carcinoma[J]. Med Oral Patol Oral Cir Bucal, 2023, 28( 2): e174- e182. DOI: 10.4317/medoral.25640. |
| [32] |
MAYER P, HAUSEN A, STEINLE V, et al. The radiomorphological appearance of the invasive margin in pancreatic cancer is associated with tumor budding[J]. Langenbeck’s Arch Surg, 2024, 409( 1): 167. DOI: 10.1007/s00423-024-03355-3. |
| [33] |
WEI L, DELIN Z, KEFEI Y, et al. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma[J]. Oncoimmunology, 2019, 9( 1): 1672495. DOI: 10.1080/2162402X.2019.1672495. |
| [34] |
ZHOU B, ZONG S, ZHONG W, et al. Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins[J]. Oncogene, 2020, 39( 7): 1527- 1542. DOI: 10.1038/s41388-019-1082-1. |
| [35] |
UNAL B, CELIK MY, GEDIK EO, et al. Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers[J]. World J Hepatol, 2023, 15( 6): 775- 785. DOI: 10.4254/wjh.v15.i6.775. |
| [36] |
SHAFIQ AM, TAHA NA, ZAKY AH, et al. Prognostic significance of the tumor budding and tumor-infiltrating lymphocytes in survival of hepatocellular carcinoma patients[J]. Int J Health Sci(Qassim), 2024, 18( 6): 10- 19.
|
| [37] |
MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9(MMP-9) and its inhibitors in cancer: A minireview[J]. Eur J Med Chem, 2020, 194: 112260. DOI: 10.1016/j.ejmech.2020.112260. |
| [38] |
FUERST R, CHOI JY, KNAPINSKA AM, et al. Development of a putative Zn 2+-chelating but highly selective MMP-13 inhibitor[J]. Bioorg Med Chem Lett, 2022, 76: 129014. DOI: 10.1016/j.bmcl.2022.129014. |
| [39] |
SANYAL S, AMIN SA, BANERJEE P, et al. A review of MMP-2 structures and binding mode analysis of its inhibitors to strategize structure-based drug design[J]. Bioorg Med Chem, 2022, 74: 117044. DOI: 10.1016/j.bmc.2022.117044. |
| [40] |
CHEN C, ZHAO SJ, KARNAD A, et al. The biology and role of CD44 in cancer progression: Therapeutic implications[J]. J Hematol Oncol, 2018, 11( 1): 64. DOI: 10.1186/s13045-018-0605-5. |
| [41] |
MA ZL, GUO DL, WANG QX, et al. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in hepatocellular carcinoma[J]. Theranostics, 2019, 9( 10): 2967- 2983. DOI: 10.7150/thno.30562. |
| [42] |
XIA LZ, OYANG L, LIN JG, et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer, 2021, 20( 1): 28. DOI: 10.1186/s12943-021-01316-8. |
| [43] |
LI ZZ, SUN CJ, QIN ZH. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming[J]. Theranostics, 2021, 11( 17): 8322- 8336. DOI: 10.7150/thno.62378. |
| [44] |
ALAWYIA B, CONSTANTINOU C. Hepatocellular carcinoma: A narrative review on current knowledge and future prospects[J]. Curr Treat Options Oncol, 2023, 24( 7): 711- 724. DOI: 10.1007/s11864-023-01098-9. |
DownLoad: